New regulatory framework for cancer drug development.
Recent changes to non-clinical cancer guidelines offer a golden opportunity to expedite the translation of new anticancer drugs into the clinic. In this review we look at how these guidelines can be implemented and how they can be integrated with non-clinical and clinical study design to produce robust and safe clinical trials.
Drug Development Office, Strategy and Research Funding, Cancer Research UK, London, UK. paul.jones@cancer.org.uk
Paul S
PS
Jones
David
D
Jones
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D055808:Drug Discovery / Q000331:legislation & jurisprudence*; D005062:European Union; D017408:Guidelines as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D006113:United Kingdom
D000970:Antineoplastic Agents